Prostate cancer is unique compared to other major cancers due to the presence of multiple
primary malignant foci in the majority of patients at the time of diagnosis. Each malignant …

Cancer evolution lays the groundwork for predictive oncology. Testing evolutionary metrics
requires quantitative measurements in controlled clinical trials. We mapped genomic …

Metastatic prostate cancer (PCa) poses a significant therapeutic challenge with high
mortality rates. Utilizing CRISPR-Cas9 in vivo, we target five potential tumor suppressor …

Single-cell sequencing is a crucial tool for dissecting the cellular intricacies of complex
diseases. Its prohibitive cost, however, hampers its application in expansive biomedical …

Greater personalization of cancer medicine continues to shape therapy development and
patient selection accordingly. The treatment of prostate cancer has evolved considerably …

We are building the world's first Virtual Child–a computer model of normal and cancerous
human development at the level of each individual cell. The Virtual Child will “develop …

Abstract Treatment resistance remains a major issue in aggressive prostate cancer (PC),
and novel genomic biomarkers may guide better treatment selection. Circulating tumor DNA …

The development of cancer is an evolutionary process involving the sequential acquisition of
genetic alterations that disrupt normal biological processes, enabling tumor cells to rapidly …

Background Extension of prostate cancer beyond the primary site by local invasion or nodal
metastasis is associated with poor prognosis. Despite significant research on tumour …

Background High tumor mutational burden (TMB) is one of the widely researched predictive
biomarkers of immune checkpoint inhibitors and has been shown to be closely related with …